Drug Label for Myozyme

The drug label for Myozyme is now available for patients to review. It includes the possible side effects...
Author: IPA
Archive
June 7, 2006

Letter From IPA and Genzyme Concerning LOTS

Dear IPA members, Pompe patients, family members and GSD-net participants, The IPA board received several questions concerning participation...
Author: IPA
Archive
June 5, 2006

Myozyme Approved in the US

Genzyme Press Release (April 28,2006) Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has...
Author: Genzyme
Archive
April 27, 2006

Myozyme Approved in Europe

Genzyme Press Release (April 3, 2006) Product is First Treatment for Pompe Disease Genzyme Corp. (Nasdaq: GENZ) announced...
Author: Genzyme
Archive
April 2, 2006

Pompe Program Update

As the new year begins, 2006 promises to be a dynamic time for the Pompe community. The first...
Author: Genzyme
Archive
February 25, 2006

Genzyme Provides Update on US Marketing Application for Myozyme

Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has extended by 90 days the...
Author: Genzyme
Archive
January 16, 2006

Pompe Survey

Patients and parents contribute to the understanding of late-onset Pompe Disease. Pompe Center, Erasmus MC, Rotterdam www.pompecenter.nl: The...
Author: Webmaster
Archive
December 31, 2005

Pompe Program Update

This is an exciting time for Pompe patients and caregivers. The BLA (Biologics License Application) was filed with...
Author: Genzyme
Archive
September 13, 2005

Genzyme Submits BLA for Myozyme for Treatment of Pompe Disease

Pivotal Trial Meets Primary Endpoint Genzyme Corp. (Nasdaq: GENZ) announced today that it has submitted a biologics license...
Author: Genzyme
Archive
July 28, 2005

Pompe Program Update

Steady progress is being made in all areas of the Genzyme Pompe program and the goal of obtaining...
Author: Genzyme
Archive
July 16, 2005
1 … 33 34 35 36 37 38